The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a more substantial loss in body mass and benefit metabolic markers, particularly concern